What is EBJIS?
The aim of the Society is to promote the knowledge of all infections affecting the Musculoskeletal system (bone and joint infections), and to promote the prevention and treatment of these infections. The Society is a non-profit organisation. The annual membership fee at this moment is 110 euro. Members who not pay their fee for 2 years are skipped as member.
There is no direct benefit of commercial parties. Since 5 years a scientific price is given for the best paper and the best poster during the annual meeting. The annual meetings are partly organised with financial help of the industry, but it appears to be difficult to get sponsoring of international meetings by national companies.
The Board consists of a President, assisted by a Vice-President (the next President) and a Past-President, all in that function for 2 years. This guarantees continuity for each of 6 years with an overlap. A General Secretary, Treasurer, Archivist, and members of the Board assist them. They can be re-elected and form a more permanent factor. The Board meets three to four times a year. The members themselves must do all administrative work; the relative small society with limited finance cannot afford professional support.
The European Bone and Joint Infection Society (EBJIS) is today an important platform for all doctors and scientists interested in infections of the musculoskeletal system, but in the first years of its existence it was not clear that it would develop to this level. In the early nineteen eighties many specialty societies were founded, and some of these rapidly acquired a large number of members, e.g. the societies devoted to hip prostheses or knee arthroscopy. The EBJIS started also in these years, but as a relative small study group. Nowadays there is a decrease of the presence at the meetings of these early members, since they are retired or have passed away. Very few of the current members are aware how much effort was needed, especially in the first years, to create the platform for bone and joint infection that is available now.